CAS NO: | 62-97-5 |
规格: | ≥98% |
包装 | 价格(元) |
5mg | 电议 |
10mg | 电议 |
25mg | 电议 |
50mg | 电议 |
100mg | 电议 |
250mg | 电议 |
500mg | 电议 |
1g | 电议 |
Molecular Weight (MW) | 389.51 |
---|---|
Formula | C20H24N.CH3O4S |
CAS No. | 62-97-5; 15394-62-4 (cation) |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: 25 mg/mL (64.2 mM) |
Water: 28 mg/mL (71.9 mM) | |
Ethanol: <1 mg/mL | |
SMILES | [O-]S(=O)(OC)=O.C[N+]1(C)CC/C(CC1)=C(C2=CC=CC=C2)\C3=CC=CC=C3 |
Synonyms | NSC41725; Diphemanil Methylsulfate; NSC 41725; NSC-41725; Prantal; Talpran; Chemical Name: 4-(diphenylmethylene)-1,1-dimethylpiperidin-1-ium methyl sulfate |
In Vitro | In vitro activity: Diphemanil Methylsulfate exerts its action by primarily binding the muscarinic M3 receptor. In addition to its well known antimuscarinic effects, Diphemanil Methylsulfate also possesses direct smooth muscle spasmolytic activity. |
---|---|
In Vivo | The pharmacokinetic experiments show that absorption of diphemanil methylsulphate is slow (tmax = 2 to 4 h), the mean half-life is 8.35 h, and the amount of the drug recovered in urine within 48 h ranges from 0.6 to 7.4% of the administered dose. Poorly absorbed from the gastrointestinal tract with an absolute bioavailability of 15 to 25%. |
Animal model | |
Formulation & Dosage | |
References | Eur J Clin Pharmacol. 1992;42(6):689-91. |